This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Venditti, J. M. Articles by Goldin, A. Search for Related Content PubMed PubMed Citation Articles by Venditti, J. M. Articles by Goldin, A.

Evaluation of Antileukemic Agents Employing Advanced Leukemia L1210 in Mice. VIII

Fifteen compounds were evaluated for their ability to increase the lifespan of mice with advanced leukemia L1210. Eleven additional compounds which had been evaluated previously in this assay system were studied more extensively. Of the compounds assayed for the first time against advanced L1210, Benzanilide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-4'-([p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]carbamoyl)-, hydrochloride (NSC-67, 734) and Cytosine, 1-ß-D-arabinofuranosyl-, hydrochloride (NSC-63,878) were 103 and 179 per cent as effective as Amethopterin (MTX) which was employed as a standard for antileukemic activity. The antibiotics, Daunomycin (53 per cent as effective as MTX) and Actinobolin (39 per cent as effective as MTX) were moderately effective. Data are presented on the influence of the treatment schedule including the time of treatment initiation, the site of tumor inoculation, or the route of drug administration on the antileukemic effectiveness of selected compounds of interest including Cytoxan (NSC-26,271), methyl-glyoxalbisguanylhydrazone, dihydrochloride (NSC-32, 946), 6-mercaptopurine (NSC-755), prednisone (NSC-10, 023E), the phthalanilide derivatives (NSC-50, 469, NSC-53, 212, and NSC-60,339), 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409,962), and two phenazinium derivatives (NSC-33,419 and NSC-33,426).

¹ Drug Evaluation Branch, Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

² Microbiological Associates, Inc., Bethesda, Maryland. This study was supported by Contract No. PH-43-62-182 from the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Public Health Service, U. S. Department of Health, Education, and Welfare.